Company leadership
Guiding research and innovation with expertise and vision

Revolutionising treatment
options for those living with
neurodegenerative diseases
Our leadership team and board bring together a wealth of experience in neuroscience, pharmaceutical development and corporate management. From research pioneers and industry executives to synthetic chemistry experts and accomplished anaesthetists, they contribute their diverse expertise to advance research and development in the field of neurodegenerative diseases.
C-Suite
Directors

Dr Carol Pringle
Regulatory Director

Dr Diane Downie
Operations Director

Gavin Birnie
Commercial Director

Gavyn Barrett
Quality Assurance Director

Hwang Hong Wei
Finance Director

Lynn Rankin
People and Culture Director

Marcus Schembri-Wischik
Head of Legal – Data Protection & Clinical Operations Alternate Director

Dr Sonya Miller
Medical Director